Merck & Co., Inc. (NYSE:MRK) announced today that its investigational antibody drug conjugate, zilovertamab vedotin, showed ...

Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial of patients with advanced CRC and NSCLC whose tumours harbour KRAS G12C mutations Rahway, New Jersey ...

The Wilmington lab is expected to be functional by 2028. "The Merck Wilmington Biotech site represents our continued commitment to growing our investments in U.S. manufacturing and has the ...

the Rahway-based company announced April 29. The Merck Wilmington Biotech facility will house laboratory, manufacturing and warehouse capabilities for the launch and commercial production of ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

In early 2024 Merck also secured approvals for a new “Building 41” to be located toward the center of the company’s 320-acre complex, a new lab analysis and testing building to be built on ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing the macro-economic and geopolitical environment as well ...